Latest rheumatoid arthritis Stories
HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress...
NEW YORK, LONDON, BERLIN, PARIS, March 19, 2013 /PRNewswire/ -- The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market [http://www.reportstack.com/product/99233/monoclonal-antibodies-market-in-rheumatoid-arthritis-to-2018-market-characterized-by-large-and-diversified-pipeline-and-low-threat-of-biosimilar-sales-erosion.html ] , constituting four of the global top 20 best-selling drugs. The...
Researchers in Manchester have found a link between several lifestyle factors and pre-existing conditions, including smoking cigarettes and diabetes, and an increased risk of developing rheumatoid arthritis. Rheumatoid Arthritis (RA) is a chronic disease which affects around 0.8% of the population; and its causes are of great interest to the medical world. Research led by Professor Ian Bruce, NIHR Senior Investigator and Professor of Rheumatology at The University of Manchester and...
d’Oliveira & Associates Win Social Security Disability Claim for Attleboro Woman Who Received Over $25,000 in Back Due Benefits [Case Number: AT-12607] (PRWEB) March 17, 2013 The attorneys at d’Oliveira & Associates recently obtained a significant award for a Massachusetts client whose case was brought before the Social Security Administration (Attleboro, MA District Court, Case Number: AT-12607). The client (whose name is withheld for confidentiality purposes) was laid off...
Up to 63% Reduction in CRP Response with ISIS-CRP Rx Treatment CARLSBAD, Calif., March 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that ISIS-CRP(Rx) selectively reduced severe elevations in C-reactive protein (CRP) in humans. Data from a Phase 1 clinical study showed that ISIS-CRP(Rx) produced statistically significant, dose-dependent reductions in CRP response following an endotoxin challenge, which produces immune responses similar to those...
Patients and doctors encouraged to discuss target uric acid levels and appropriate treatment plan to avoid gout flares and long-term complications PITTSBURGH, March 12, 2013 /PRNewswire/ -- The Gout & Uric Acid Education Society (GUAES) has added six new educational videos for patients and medical professionals to its library of popular educational videos on gout, highlighting the society's most important takeaways from the recently released American College of Rheumatology (ACR)...
26 countries can't afford certain disease modifying drugs, so excluding 320 million people This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers. DMARDs are extremely effective for the treatment of rheumatoid arthritis, and the European League Against Rheumatism (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt...
Regeneron receives 4% to 15% royalty on sales of Ilaris TARRYTOWN, N.Y., March 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will receive an additional potential royalty stream now that the European Commission (EC) has approved Novartis' llaris (canakinumab, ACZ885) in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options....
Hundreds Will Urge Congress for More Arthritis Support in Person or through Virtual Summit on March 4-6 LOS ANGELES, Feb. 28, 2013 /PRNewswire-USNewswire/ -- Fourteen-year-old Jonathan Corthell of Henderson, NV will be traveling 2,400 miles to Washington, D.C. to ask Congress to support policies that will ensure more research, better treatments and greater access to care for those with arthritis, the nation's leading cause of disability. Corthell, who has suffered with Juvenile...
Survey finds that this common ailment has a big impact on quality of life ROCKLIN, Calif., Feb. 27, 2013 /PRNewswire-USNewswire/ -- Most people expect some aches and pains due to arthritis as they age, but a new survey by the American Chronic Pain Association (ACPA) finds that many with arthritis face significant disability due to the condition. In addition, those with arthritis live with fears about the course of their condition. In combination, these factors erode quality of...
